Infusion for Health Bets Big on Home Care with Strategic Hire

BREA, CA – July 14, 2026 – In a move that signals a significant strategic pivot toward decentralized healthcare, Infusion for Health, a prominent provider of specialty infusion services, is aggressively expanding its Home Infusion division. The expansion is bolstered by the high-profile addition of Michael Rigas, Pharm.D. FNHIA, an industry pioneer with a four-decade track record of building national home infusion enterprises. This initiative, backed by private equity firm Oak HC/FT, positions the company to capitalize on the powerful, market-shaping trend of moving complex medical care from the clinic into the patient's home.

Infusion for Health has already established a strong foothold in the Western U.S. with its network of ambulatory infusion centers. Now, by integrating a robust home infusion service, the company is creating a comprehensive site-of-care model designed for maximum flexibility. “Our vision is to deliver infusion care wherever it best serves the patient,” said Dan McCarty, CEO of Infusion for Health. “Expanding our home infusion capabilities alongside our ambulatory infusion center network allows us to offer greater flexibility while maintaining the clinical excellence and patient experience that define our organization.”

Tapping into a Surging Market

Infusion for Health’s strategic push is not happening in a vacuum. It is a calculated entry into one of healthcare's most rapidly growing sectors. The global home infusion therapy market, valued at approximately $41.7 billion in 2025, is projected to soar to nearly $79 billion by 2033. This explosive growth is fueled by a convergence of powerful forces: an aging population, a rising prevalence of chronic conditions requiring long-term treatment, and overwhelming patient demand for care that is both convenient and cost-effective.

Patients and payers alike are recognizing the benefits. Home infusion is not only more comfortable for patients but also significantly less expensive than hospital-based care, with studies showing potential savings of $1,900 to $2,900 per treatment course. Furthermore, research indicates that clinical outcomes in the home are often comparable or even superior to those in traditional settings, partly due to a lower risk of hospital-acquired infections.

The competitive landscape is a complex mix of large national providers like Option Care Health and CVS Health’s Coram, vertically integrated giants such as Optum, and a fragmented array of regional and local agencies. Success in this space requires sophisticated clinical expertise, robust operational capabilities, and the ability to navigate a complex regulatory environment, particularly the reimbursement rules set by the Centers for Medicare & Medicaid Services (CMS). Infusion for Health's investment suggests it is preparing to compete on all these fronts.

The Rigas Effect: Acquiring an Industry Architect

The decision to bring Michael Rigas aboard is perhaps the clearest indicator of the company’s ambition. Dr. Rigas is not merely an experienced executive; he is widely regarded as one of the architects of the modern home infusion industry. As a co-founder of KabaFusion, he was instrumental in building that company into a nationally recognized home infusion leader. His resume also includes executive leadership roles at major healthcare organizations like Apria Healthcare and Geisinger Health System.

His standing is further solidified by his designation as a Fellow of the National Home Infusion Association (FNHIA), a title reserved for individuals who have made sustained and significant contributions to the field. This move is less about filling a position and more about acquiring a deep well of strategic knowledge and operational expertise.

“As we continue expanding our home infusion footprint, we are intentionally building a team with deep expertise and a shared commitment to clinical excellence,” said Jeffrey Shore, Sr. VP of Operations at Infusion for Health. “Michael’s experience and vision have helped shape the industry, and his guidance will be invaluable as we continue expanding access for patients and providers.”

For his part, Dr. Rigas sees the move as an opportunity to build upon a strong foundation. “The future of infusion care is about providing patients and providers with options while maintaining the highest standards of safety, quality, and service,” said Dr. Rigas. “Infusion for Health has built an outstanding reputation in ambulatory infusion care, and I am excited to join the team as they continue expanding their home infusion capabilities and extending that same level of excellence into the home.”

A Playbook for Private Equity-Fueled Growth

Behind this strategic expansion is the guiding hand of Oak HC/FT, the venture growth-equity firm backing Infusion for Health. The move aligns perfectly with the investment thesis common among healthcare-focused private equity firms: identify a high-growth market driven by durable trends and back a company with the leadership and strategy to capture a significant share. The shift to decentralized, lower-cost care settings is one of the most powerful trends in healthcare today.

By supporting the expansion into home infusion, Oak HC/FT is enabling its portfolio company to become a more comprehensive and therefore more competitive player. Creating an integrated model that offers both ambulatory and home-based care options not only meets patient demand but also creates a stickier relationship with referring physicians and health systems. The strategic recruitment of a proven leader like Dr. Rigas serves to de-risk the expansion and accelerate the path to profitability and market leadership, demonstrating a classic private equity playbook for value creation in a dynamic industry.